Pfizer Azione

Pfizer EBITDA

Il EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) di Pfizer (PFE) al 22 ago 2026 è 15,07 miliardi USD. L'anno precedente, EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) era 15,86 miliardi USD — una variazione del -4,98% (inferiore).

EBITDA

15,07 miliardiUSD

YoY

-4,98%

Ultimo aggiornamento:

EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) di Pfizer ammonta a 2026 15,07 miliardi USD. EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) di Pfizer ammontava a 2025 15,86 miliardi USD. Diminuisce del -4,98% inferiore rispetto all'anno precedente.
Access this data via the Eulerpool API

Pfizer Analisi delle Azioni

Cosa fa Pfizer? Pfizer Inc, one of the world's largest and most well-known pharmaceutical companies, has made significant advancements in the medical industry throughout its approximately 170-year history. The company is headquartered in New York City and has offices in over 150 countries. Pfizer was founded in 1849 by two cousins, Charles Pfizer and Charles Erhart, who opened their first factory in Brooklyn to produce pure crystalline chinasalt. They later expanded their business and began synthesizing chemical compounds, leading them to enter the pharmaceutical industry. In the following years, Pfizer made some significant discoveries, including the synthesis of antibiotics such as penicillin and terramycin. In the 1990s, the company expanded its portfolio and became a leading provider of prescription drugs, immunological medications, and animal health products. Today, the company focuses on three core areas: innovative health products, patented medications, and generic products. Pfizer invests millions of dollars in research and development of new and innovative treatment options, including cancer drugs, therapies for neurological disorders, cardiovascular diseases, and immunology products. Another important aspect of Pfizer's business model is its partnerships with other companies and organizations. The company works closely with universities, research institutions, governments, and other companies to form partnerships that allow for collaborative development of new products. Some of Pfizer's most well-known products include Viagra, Lipitor, Celebrex, Zoloft, and Lyrica. Viagra is used to treat erectile dysfunction in men. Lipitor is a cholesterol-lowering medication that reduces the risk of cardiovascular diseases. Celebrex is an anti-inflammatory medication used to treat pain and inflammation. Zoloft is an antidepressant used to treat various mental disorders. Lyrica is a prescription medication used to treat pain and seizures. In recent years, Pfizer has also taken a leading role in the development of vaccines against COVID-19, collaborating with the German company BioNTech to develop a promising vaccine candidate. The vaccine provides protection against the virus, particularly against severe illness. Over the years, the company has faced concerns regarding the use of medications, such as the scandal surrounding the pain reliever Vioxx, which was withdrawn in 2004 after being associated with an increased risk of cardiovascular diseases. Pfizer has since strengthened its research and development standards and partnerships to ensure the safety and efficacy of its products. In summary, Pfizer is a global player in the pharmaceutical industry. The company heavily invests in research and development of new products to provide innovative treatment options, secures patents, and simultaneously keeps its portfolio up-to-date with generic products to remain competitive in the industry. The company will continue to contribute to improving healthcare worldwide by developing lifesaving medications and vaccines that enable people to lead better lives. Pfizer è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Pfizer azioni

EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) di Pfizer è 15,07 miliardi USD nel 2026.

Il EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) di Pfizer è passato da 15,86 miliardi USD a 15,07 miliardi USD, con una variazione del -4,98 %. Il valore è inferiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del Pfizer di EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) dal 2006, con valori annuali, grafici e analisi dettagliate.

L'EBITDA misura la performance operativa prima dell'impatto della struttura finanziaria, dell'ambiente fiscale e degli oneri di ammortamento non monetari.

EBITDA = EBIT + Ammortamenti e svalutazioni

Il USD di EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) è un fattore chiave per gli investitori. I cambiamenti in questa metrica possono segnalare il miglioramento o il deterioramento dei fondamentali, impattando direttamente il prezzo delle azioni. Su Eulerpool puoi tracciare il Pfizer di EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) storicamente e in tempo reale.

Access this data via the Eulerpool API

Conto economico — Pfizer

Tutte le Metriche Finanziarie — Pfizer